Aethlon Medical advances Hemopurifier oncology study to third cohort

• Aethlon Medical completed the second cohort of its oncology feasibility study for the investigational Hemopurifier device.
• The company expects to enroll patients in a third cohort to analyze combined data for dose-response patterns.
• Management stated that larger trials will be necessary to properly evaluate any potential clinical benefit.

Aethlon Medical (NASDAQ:AEMD) reported that patients in the second cohort of its oncology feasibility study exhibited biological changes.

These observed changes replicated biomarker shifts that the company previously recorded in the first cohort of the trial.

The current study evaluates the safety and dosing of the Hemopurifier in patients with advanced solid tumors.

Researchers recorded reductions in tumor-associated microRNAs alongside numerical increases in total and tumor-specific T-cell populations during the study.

Aethlon Medical stated that these preliminary findings are strictly descriptive observations from an early-stage feasibility trial.

The company noted that this current phase is not designed to demonstrate independent clinical efficacy.